CHIP at a VAF of 10% or greater is the strongest predictor of whether daily low-dose aspirin can help prevent cancer in healthy, older adults.

IDH1 inhibitors show strong efficacy and tolerability in IDH1-mutated AML and MDS, with some patients achieving long-term ...

So when you look at the treatment differences versus sham, this results in about a 20.7% treatment difference when you compare the low-dose group compared to ... And this included measurements such as ...

Community-acquired pneumonia is a major global health challenge that disproportionately affects vulnerable populations, ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

A new arthritis treatment in Greensboro is giving patients relief without surgery. One woman says low-dose radiation changed ...

Staphylococcus aureus infections remain a formidable health threat, responsible for the most infection-related deaths ...

Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Treating oncologists have a high index of suspicion for irAEs and a low threshold for initiating treatment. The role of the neurologist is to consider the differential diagnosis, direct investigation ...